Independent factors FOR poor prognosis in young patients with stage I-III breast cancer. 2020

Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
1Josip Juraj Strossmayer University in Osijek, Faculty of Medicine, Osijek, Croatia; 2Osijek University Hospital Centre, Osijek, Croatia.

Breast cancer is the most common malignancy in the population of women under 40 years of age. Young age is an independent factor for poor prognosis. In this research, we tried to establish other factors for poor prognosis in stage I-III breast cancer. The following parameters were observed: tumor size, lymph node status, histologic grade, hormonal receptor status, Ki-67 prognostic index, Her2 neu status, histologic type of the tumor, local recurrence and metastases. Logistic regression was used to evaluate the effect of specific factors on the probability of lethal outcome and development of distant metastases. Our patients showed a predominance of T1 tumor (49.4%), had positive lymph nodes (62%) and most of them were pN1 (61.2%). Up to one-third of patients had triple negative status. Ki-67 proliferation index was high (25%). Multicentric tumor was detected in 23% of patients. There was no difference in overall survival between the two types of surgical procedures. Patients with pN0 status had better overall survival. Breast cancer in the population of young women has a more aggressive nature. Study results indicated positive lymph node status as an independent factor for poor prognosis of stage I-III breast cancer.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
December 2023, Journal of surgical oncology,
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
September 2021, Journal of cancer research and clinical oncology,
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
March 1983, Kyobu geka. The Japanese journal of thoracic surgery,
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
November 2016, Breast cancer research and treatment,
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
September 2012, Nihon rinsho. Japanese journal of clinical medicine,
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
December 2023, Frontiers in bioscience (Landmark edition),
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
September 2021, Journal of cancer research and clinical oncology,
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
August 1979, Annals of surgery,
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
October 2016, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Ivan Erić, and Anamarija Petek Erić, and Ivan Koprivčić, and Marko Babić, and Stana Pačarić, and Bojan Trogrlić
March 2013, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Copied contents to your clipboard!